tirzepatide osa approval The FDA has expanded the of Eli Lilly's obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity — the first medication approved for the Diabetes drug resolves sleep apnea

Semaglutide works by slowing stomach emptying and signaling fullness to your brainbut exceeding your prescribed dose amplifies these effects beyond therapeutic benefit, potentially causing acute gastrointestinal distress and metabolic instability

doi: 10.1128/jvi.68.7.4650-4655.1994 190 CartwrightEKSpicerLSmithSALeeDFastRPaganiniSet al

It is available to patients with a body mass index (BMI) of over 30 kg/m or individuals with a BMI of over 27 kg/m alongside at least one weight-related condition, such as type 2 diabetes, prediabetes, high cholesterol, or sleep apnea

Doi: 10.3390/molecules26144285 Hong N, Ye Z, Lin Y, Liu W, Xu N, Wang Y

Access can be challenging for patients without a drug plan, as treatment with naltrexone or acamprosate costs approximately $1,800 annually

The 72-week STEP UP trial was a randomised, double-blinded, parallel-group, placebo-controlled, superiority trial designed to evaluate the efficacy of semaglutide 7.2mg with semaglutide 2.4mg and placebo as an adjunct to lifestyle intervention